LC-MS/MS method for quantitatively analyzing plasma concentration of antituberculous drug

A technology of LC-MS and anti-tuberculosis drugs, which is applied in the direction of analyzing materials, measuring devices, and material separation. low cost effect

Pending Publication Date: 2021-06-08
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are mainly liquid chromatography, liquid phase-tandem mass spectrometry (LC-MS/MS) and ultra-high performance liquid phase-tandem mass spectrometry (UPLC-MS/MS) methods for detecting the plasma concentration of anti-tuberculosis drugs at home and abroad. In some methods, only one anti-tuberculosis drug is detected, the detection time is long, and the detection component is single, which is not suitable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • LC-MS/MS method for quantitatively analyzing plasma concentration of antituberculous drug
  • LC-MS/MS method for quantitatively analyzing plasma concentration of antituberculous drug
  • LC-MS/MS method for quantitatively analyzing plasma concentration of antituberculous drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0040] The present invention will be further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto.

[0041]An embodiment of the present invention provides a LC-MS / MS method for quantitatively analyzing the plasma concentration of anti-tuberculosis drugs, comprising the following steps:

[0042] S1 standard working solution preparation:

[0043] a. Weigh 12.47mg of isoniazid into a 10mL volumetric flask with an electronic balance, dissolve it with methanol and constant volume, mix it upside down, and prepare a standard working solution of isoniazid whose concentration is converted to 1.245mg / mL by the correction factor; the same method, Weigh 12.89 mg of rifampicin to prepare the standard working solution of rifampicin with a concentration of 1.274 mg / mL, and weigh 12.47 mg of the ethambutol reference substance to prepare a standard working solution of ethambutol with a concentration of 0.916 mg / mL; Weigh ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Collision energyaaaaaaaaaa
Collision energyaaaaaaaaaa
Login to view more

Abstract

The invention discloses an LC-MS/MS method for quantitatively analyzing the plasma concentration of an antituberculous drug. The method can simultaneously detect isoniazide, rifampicin, pyrazinamide and ethambutol through S1 standard working solution preparation, S2 sample preparation, S3 sample treatment, S4 sample detection and S5 standard curve making and quantitative analysis, the sample pretreatment process is simple and is easy to operate, and all the reagents are conventional reagents, so that the cost is lower. According to the method, a reversed-phase C18 column of 150 mm*2.1 mm is adopted, the flow rate is controlled to be 0.3 mL/min, and the column temperature is 30 DEG C; the problem that the polarity difference of isoniazide, rifampicin, pyrazinamide and ethambutol is large can be well solved, the separation effect is better, and the cost is lower. The method has the advantages of higher sensitivity, accuracy and precision, wide detection linear range and short detection time, and can be used as a reliable detection method suitable for popularization and for monitoring the treatment concentration of clinical first-line anti-tuberculosis drugs.

Description

technical field [0001] The invention belongs to the technical field of drug analysis, in particular to an LC-MS / MS method for quantitatively analyzing plasma concentrations of anti-tuberculosis drugs. Background technique [0002] Tuberculosis is an infectious disease caused by patients infected with Mycobacterium tuberculosis. The current clinical treatment plan is the long-term combined application of various anti-tuberculosis drugs, among which rifampicin (RFP), isoniazid (Isoniazid, INH) , Pyrazinamide (PZA) and ethambutol (Ethambutol, EMB) belong to the first-line anti-TB drugs. Because tuberculosis patients are usually combined with other diseases and use multiple drugs at the same time, coupled with individual differences in patients, the concentration of anti-tuberculosis drugs in the human body varies greatly. If the drug concentration in the body is too low, the therapeutic effect cannot be achieved; if the drug concentration in the body is too high, it will cause...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/89
CPCG01N30/89
Inventor 王医成谭志荣李丽
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap